Loading organizations...
Key people at Coronet.
Coronet is a direct manufacturer of architectural LED lighting products and commercial luminaires based in Totowa, New Jersey. The organization operates a dedicated local manufacturing facility and an adjacent showroom to supply architectural lighting solutions directly to design communities, architects, and lighting professionals. Operating with a workforce of approximately 255 employees, the enterprise manages the engineering, fabrication, and assembly of its LED fixtures to generate an estimated $50.4 million in annual revenue. To distribute its commercial lighting systems throughout the New York metropolitan area and other broader domestic markets, the manufacturer utilizes a network of direct distribution channels alongside regional representatives, highlighted by a strategic partnership with Electric Lighting Agencies. Coronet was originally established in 1960 by currently undisclosed founders to serve the expanding commercial architectural sector with specialized illumination hardware and custom lighting designs.
Key people at Coronet.
Coronet Ventures is the Singapore-based venture investment arm of Cedars-Sinai Intellectual Property Company (CSIP), the innovation division of Cedars-Sinai Medical Center, focused on early-stage healthcare and biomedical startups.[1][2][4] Its mission is to build innovative companies that advance patient outcomes worldwide by bridging innovations from global hubs like Singapore and the Netherlands to the U.S. market, leveraging Cedars-Sinai's health system for piloting, scaling, and commercialization.[1][2] The firm targets "first-in-class and best-in-class" solutions in diagnostics, pharmaceuticals, medical devices, and digital health, providing portfolio companies with access to clinical trials, key opinion leaders, IP protection, FDA support, and the Cedars-Sinai Accelerator network.[1][2] As a joint venture with SEEDS Capital, it emphasizes U.S.-synergistic technologies from innovative economies.[4]
Launched as CSIP's first international investment initiative, Coronet Ventures established its Singapore operations to scout and fund regional biomedical startups, building on Cedars-Sinai's U.S. reputation and global partnerships.[1][2] Key leaders include CEO Nirdesh Gupta and Investment Director Colin Tan, both based in Singapore.[4] The firm has evolved from a U.S.-centric accelerator (supporting over 100 companies since 2017) to a global investor, with a notable 2023 fund commitment and lead investments like the US$7M seed round in Aevice Health's remote monitoring tech in May 2025.[1][3][4] This expansion deepens ties with partner nations, nurturing startups for Cedars-Sinai's mission of quality healthcare and IP commercialization.[1][2]
(Note: Search results reference a separate "Coronet" portfolio company that raised $175M, but context confirms this query targets the investment firm; the other appears unrelated.[5])
Coronet Ventures rides the wave of global healthcare innovation convergence, connecting Asia/Europe's R&D hubs to the U.S.'s massive market amid rising demand for AI-driven diagnostics, digital health, and chronic disease tools.[1][2][3] Timing aligns with post-pandemic acceleration in remote monitoring (e.g., Aevice investment) and biomed cross-border scaling, fueled by U.S. regulatory pathways and health system pilots.[1][3] Market forces like aging populations, IP commercialization needs, and Cedars-Sinai's data/clinical resources favor its model, influencing the ecosystem by de-risking international startups and fostering U.S.-Asia synergies in a fragmented $4T+ global healthcare sector.[1][2]
Coronet Ventures is poised to expand its portfolio amid booming digital health and biomed demand, potentially deepening Netherlands investments and chasing larger Series A/B rounds post its 2023 fund commitment.[1][4] Trends like AI diagnostics, personalized medicine, and U.S. market entry barriers will shape its path, amplifying Cedars-Sinai's global influence through more high-impact exits and collaborations.[1][2] As international healthcare M&A heats up, expect Coronet to solidify as a key bridge-builder, turning regional innovations into worldwide patient wins—echoing its core mission from day one.[1]
